Pharma Deals Review, Vol 2004, No 50 (2004)

Font Size:  Small  Medium  Large

Millennium Grants GSK European Marking Rights to Integrilin®

Business Review Editor

Abstract


Millennium granted GlaxoSmithKline the rights to commercialize the blood clot inhibitor Integrilin® in Europe. Millennium reacquired the drug rights from Schering-Plough.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.